Asgard Therapeutics receives third EIC grant to prepare its cancer immunotherapy for clinical trials
Cristiana Pires, CEO of Asgard Therapeutic
Lund, Sweden – SmiLe Venture Hub portfolio company Asgard Therapeutics has been awarded a €2.5 million European Innovation Council (EIC) Accelerator grant, marking the third time the company has secured funding from the EIC. The funding will support the advancement of AT-108, the company's lead cancer immunotherapy programme, towards first-in-human clinical studies planned for 2027.
Founded as a spin-out from Lund University by Cristiana Pires, CEO, Fábio Rosa and Filipe Pereira, Asgard Therapeutics is developing AT-108, a first-in-class off-the-shelf immunotherapy designed to directly reprogram tumor-resident cells in the body into antigen-presenting dendritic-like cells and trigger a personalised anti-tumour immune response.
The EIC Accelerator is one of Europe's most competitive innovation funding programmes, supporting breakthrough technologies with significant commercial and societal potential. In addition to the grant, the award makes Asgard Therapeutics eligible for up to €10 million in potential equity investment from the EIC Fund, the organisation's investment arm.
“Securing EIC funding for the third time is an outstanding achievement, reflecting the strength of Asgard’s science and the team’s ability to deliver on an ambitious vision. SmiLe Venture Hub has supported Asgard through our incubator program since 2020, and we are deeply impressed by their progress,” says Malin Sjöö, Chief Innovation Officer, SmiLe Venture Hub.
About SmiLe Venture Hub
SmiLe is a leading venture hub that specializes in advancing life science and foodtech startups from concept to commercialization. We offer comprehensive support through every stage of entrepreneurship, including tailored incubation and acceleration programs, a variety of educational courses, and access to top-tier lab facilities. To date, our flagship incubator program has supported over 120 startups, facilitating their collective acquisition of more than EUR 1.19 billion in venture capital and contributing to 21 successful IPOs. Recognized as one of Europe’s leading startup hubs in 2024 by the Financial Times and Statista, SmiLe continues to be a catalyst for innovation in the life sciences sector. As a non-profit entity based in Lund, Sweden, SmiLe is supported by Region Skåne, Lund Municipality, Lund University, and Medicon Village. We are also backed by our partners Agilent, Sony, Sparbanken Skåne, Høiberg, Ascente Law, Zacco, ChemoMetec, Samplix, Qiagen, Bio-Rad, Zeiss, SmartStone Nordics, Säkra, Servier and AbbVie Scandinavia. For more information: www.smileventurehub.com